ClearLax Label Reiterates Short-Term Use for Occasional Constipation
ClearLax’s current OTC label keeps the focus narrow: polyethylene glycol 3350 is positioned as an osmotic laxative for relief of occasional constipation, with a typical bowel movement expected in one to three days. The product is formulated as a powder for solution, with 17 g per dose when the cap is filled to the marked line. For patients and clinicians, the label reads like a standard reminder of how this class works at the bedside—retain water in the intestinal lumen, soften stool, and allow transit to resume without stimulant-driven cramping.
The product is marketed as a human OTC drug label under an abbreviated new drug application, and the packaging comes in multiple bottle sizes. Those details matter less for pharmacology than for access, but they signal the drug’s place in routine self-care for constipation rather than in treatment of complex bowel disease. ClearLax is explicitly described as unflavored, grit-free, and sugar-free, and the label notes that it contains no inactive ingredients.
A single sentence in the dosing section captures the intended scope of use: once daily, for no more than seven days unless a doctor advises otherwise.
Osmotic Action and What Patients Should Expect
Polyethylene glycol 3350 is not a stimulant laxative, and that distinction shapes both efficacy and tolerability. By drawing water into the stool, it softens desiccated fecal material and increases stool volume, which can trigger a bowel movement without forcing the colon to contract more aggressively. In practical terms, that mechanism often produces a gentler profile than stimulant agents, but it also means the effect is gradual rather than immediate. The label’s expected 1- to 3-day time frame fits that pharmacology.
The directions are straightforward for adults and children 17 years of age and older: use once a day, fill the cap to the top of the white section marked 17 g, and dissolve the powder in 4 to 8 ounces of beverage at any temperature before drinking. The label also warns not to drink the mixture if clumps remain, and not to combine the powder with starch-based thickeners used for difficulty swallowing. Those instructions point to an important real-world issue: the drug depends on complete dissolution to deliver a uniform dose and avoid swallowing problems.
Loose, watery, more frequent stools can occur during use. For a medication whose action is to retain water in the bowel, diarrhea is the predictable extension of the same mechanism when the osmotic effect overshoots the desired range.
Kidney Disease, Abdominal Pain, and Other Red Flags
The label draws a firm line around kidney disease. Patients with kidney disease are instructed not to use the product except under the advice and supervision of a doctor. That caution is clinically sensible because osmotic agents can complicate fluid and electrolyte balance, especially in patients whose renal reserve is already limited. The label also advises medical review before use if nausea, vomiting, abdominal pain, a sudden change in bowel habits lasting more than two weeks, or irritable bowel syndrome are present. In a patient with persistent or changing gastrointestinal symptoms, constipation may be a symptom rather than the diagnosis.
Stop use and ask a doctor if rectal bleeding occurs, if nausea, bloating, cramping, or abdominal pain worsen, if diarrhea develops, or if a laxative is needed for longer than one week. Those warnings are not cosmetic. Rectal bleeding and escalating pain can indicate obstruction, inflammatory disease, or another serious condition, and prolonged laxative use can obscure the underlying problem instead of solving it.
One point stands out sharply: this is a short-term constipation medicine, not a default answer for chronic bowel dysfunction.
Pregnancy, Breastfeeding, and Medication Review
Pregnant or breast-feeding patients are instructed to ask a health professional before use. The label also recommends asking a doctor or pharmacist before use if taking a prescription drug. Polyethylene glycol 3350 is generally viewed as locally acting in the gut, but medication review still matters because constipation often coexists with polypharmacy, reduced mobility, opioid exposure, or chronic disease. A simple OTC laxative can be useful, yet it should not become a substitute for evaluating medication-induced constipation or an evolving gastrointestinal disorder.
The overdose instruction is equally direct: seek medical help or contact Poison Control immediately. For an OTC product meant to be used once daily in a measured amount, overdose concerns are less about toxicity in the narrow sense and more about excessive diarrhea, dehydration, and symptom confusion in vulnerable patients.
Packaging, Strength, and Regulatory Identity
Each dose contains 17 g of polyethylene glycol 3350, and the label identifies three bottle presentations: 238 g, 510 g, and 850 g. The 238 g bottle is the branded consumer size shown on the principal display panel, which describes 14 once-daily doses. The product was first marketed in 2009, with an additional package size added in 2019. The label update now on record is dated October 13, 2026.
For clinicians, the regulatory identity is ordinary but useful. ClearLax is positioned as an OTC equivalent to the active ingredient in MiraLAX, and the therapeutic claim remains limited to relief of occasional constipation and irregularity. There is no suggestion of a broader indication, no special subpopulation claim, and no hidden complexity in the formulation. That simplicity is part of why polyethylene glycol has remained a common self-care option: predictable osmotic action, minimal formulation burden, and a dosing scheme patients can follow without titration.
Why This Label Matters at the Bedside
Constipation is often treated casually, yet the label draws several clinically meaningful boundaries. It tells patients when not to self-treat, how long to continue, and which symptoms should trigger escalation. For clinicians, those boundaries align with a common diagnostic challenge: distinguishing transient functional constipation from bowel pathology, medication effects, obstruction, or inflammatory disease. Osmotic laxatives can soften stool, but they do not diagnose the reason stool became hard in the first place.
The label’s conservative framing is deliberate. ClearLax is meant for occasional irregularity, not chronic dependence, and its safety instructions are built to keep self-treatment from masking red-flag symptoms. In that sense, the most important message is not the brand name or the package size. It is the narrow therapeutic window around a familiar drug: use enough to relieve constipation, but not enough to ignore the cause when constipation stops being occasional.